Clinical Trial Update: Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases [Phase 4]

View source ↗

Summary

This update covers a Phase 4 trial of lorlatinib in ALK-positive non-small cell lung cancer patients with brain or leptomeningeal metastases. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer with Brain Metastases
• Non-small Cell Lung Cancer with Leptomeningeal Metastases

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Carcinoma, Non-Small-Cell Lung, Brain Metastases | Phase 4 | Status: ACTIVE_NOT_RECRUITING